Cargando...
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attenti...
Gardado en:
Publicado en: | J Clin Invest |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado: |
American Society for Clinical Investigation
2017
|
Assuntos: | |
Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5451217/ https://ncbi.nlm.nih.gov/pubmed/28504649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89548 |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|